HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

eletriptan (Relpax)

5-HT(1B/1D) receptor agonist; structure in first source

Also Known As:

Relpax; 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide; Mack brand of eletriptan hydrobromide; Pfizer brand of eletriptan hydrobromide; UK 166,044; UK 166044; UK-166,044; UK-166044; eletriptan hydrobromide

Networked: 111 relevant articles (39 outcomes, 43 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Almas, Mary: 8 articles (04/2014 - 08/2006)
2.	Hettiarachchi, Jayasena: 6 articles (02/2007 - 07/2003)
3.	Diener, Hans-Christoph: 5 articles (04/2011 - 01/2002)
4.	Hettiarachchi, J: 5 articles (02/2005 - 02/2002)
5.	Ramos, Elodie: 4 articles (01/2015 - 02/2014)
6.	Ferrari, M D: 4 articles (06/2011 - 01/2000)
7.	Albert, Kenneth S: 4 articles (02/2008 - 07/2006)
8.	Parsons, Bruce: 4 articles (02/2008 - 02/2007)
9.	Prous, J R: 4 articles (09/2007 - 07/2004)
10.	Rabasseda, X: 4 articles (09/2007 - 07/2004)

Related Diseases

1.	Migraine Disorders (Migraine) 04/01/2007 - "Eletriptan is a potent 5-HT(1B/1D) agonist with proven efficacy in the acute treatment of migraine in adults. " 11/28/2000 - "Eletriptan is a 5-HT(1B/1D) receptor agonist with proven efficacy in the acute treatment of migraine. " 12/01/2000 - "In this placebo-controlled trial, eletriptan produced a significant reduction in the loss of usual functioning time associated with a migraine attack. " 04/01/2005 - "Eletriptan has been shown to be effective and well tolerated in randomised, double-blind, placebo-controlled acute migraine trials and long-term open-label trials. " 01/01/2007 - "Eletriptan 20 mg, 40 mg and 80 mg are effective for the treatment of an acute migraine attack. "
2.	Headache (Headaches) 07/01/2003 - "In clinical trials, eletriptan improved the headache response rate with rapid onset, and reduced headache recurrence. " 04/01/2010 - "Among patients with prospectively identified MM, eletriptan 20 mg 3 times daily effectively reduced MM. A significant reduction in headache activity occurred for 53% of patients." 10/01/2004 - "The headache improved after administration of eletriptan hydrobromide. " 03/01/2004 - "The 2-h post-dose headache response rates (i.e., the primary efficacy endpoint) of Japanese migraineurs to eletriptan 20, 40 and 80 mg were 64, 67 and 76%, respectively; European and American migraineurs showed similar trends and, in these studies, eletriptan was significantly superior to placebo (p < 0.05). " 02/01/2014 - "Adverse events were comparable between group 1 and group 2. Two-hour headache outcome measures were similar in women treated with eletriptan both within and outside of the defined menstrual time period (menses days -1 to +4). "
3.	Epilepsy (Aura) 10/01/2004 - "To test this hypothesis we evaluated the efficacy of eletriptan 80 mg taken during aura. " 10/01/2004 - "Eletriptan was well tolerated and did not prolong the aura phase. " 10/27/2000 - "Eletriptan, a second-generation triptan with high affinity for 5-HT(1B/1D) receptors, is highly effective in migraine, with or without aura. " 07/01/2003 - "In a double-blind, parallel group, placebo-controlled multicentre study, patients with and without aura (n = 446) were randomized to 40 mg eletriptan (E40, n = 188), 80 mg eletriptan (E80, n = 171) or placebo (n = 87) for treatment of up to three migraine attacks. " 10/01/2004 - "Of 123 patients randomized, 87 (71%) were treated with a double-blind, one attack, during the aura phase before headache, dose of either eletriptan 80 mg (n = 43; 74% female; mean age, 40 years), or placebo (n = 44; 82% female; mean age, 40 years). "
4.	Pain (Aches) 09/01/2005 - "Pain intensity at the time of taking eletriptan appeared to influence outcome more than the timing of the dose relative to headache onset. " 09/01/2005 - "Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing." 02/01/2002 - "In the initial attack, significantly more eletriptan patients reported headache relief and complete pain relief at 2 h vs. placebo (40 mg 62% and 32%, 80 mg 65% and 34%, placebo 19% and 3%; P < 0.0001). " 08/01/2006 - "The median times to meaningful pain relief measured by stopwatch were 84, 72, and 93 minutes for eletriptan 40 mg, eletriptan 80 mg, and rizatriptan 10 mg, respectively (log-rank P = 0.029, eletriptan 80 mg vs rizatriptan 10 mg). " 07/01/2003 - "Eletriptan is considered to reduce neuronal transmission of pain by causing vasoconstriction of dilated cranial vessels and inhibiting the release of neuropeptides from trigeminal nerves via activation of the 5-HT(1B/1D) receptors. "
5.	Cluster Headache (Cluster Headaches) 04/01/2004 - "To further evaluate the efficacy of eletriptan in the short-term prophylaxis of cluster headache. " 04/01/2004 - "This small open-label study suggests that eletriptan 40 mg twice daily may be useful for the short-term prophylaxis of cluster headache." 04/01/2004 - "The number of cluster headache attacks was recorded during a baseline period of 6 days, and during 6 days of treatment with eletriptan 40 mg twice daily. " 04/01/2004 - "A beneficial prophylactic effect from eletriptan 40 mg given to a single patient with cluster headache was observed. " 04/01/2004 - "Eletriptan for the short-term prophylaxis of cluster headache."

Related Drugs and Biologics

1.	Pain-Free
2.	Sumatriptan (Imigran)
3.	rizatriptan (Maxalt)
4.	eletriptan (Relpax)
5.	almotriptan (Axert)
6.	Serotonin (5 Hydroxytryptamine)
7.	naratriptan
8.	zolmitriptan (Zomig)
9.	frovatriptan (Allegro)
10.	Tryptamines (Triptans)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Stents
3.	Nebulizers and Vaporizers (Inhaler)
4.	Oral Administration